Navigation Links
IdentiPHI Re Launches SAFmodule Software to Secure Novell(R) Networks
Date:9/20/2007

thenticator(TM), an add-on product to SAFmodule that enables strong authentication over Citrix(R) MetaFrame, Windows(R) Terminal Services and XP Remote Desktop sessions.

About IdentiPHI

Headquartered in Austin Texas, IdentiPHI is an innovative technology company offering a comprehensive suite of enterprise security solutions and consulting services. Comprised of experienced partners and thought-leaders in the industry, IdentiPHI is setting the standard for what companies are looking for in security solution. IdentiPHI provides flexible tools that meet or exceed current legislation requirements to strengthen identity management and authentication systems. We are defining security technology to meet the evolving challenges of today's fast-paced business needs. IdentiPHI announced this month that they have entered into a definitive merger agreement under which Saflink and IdentiPHI will combine into a single, publicly held company. For more information please call our toll free line at 888-436-8744, or visit http://www.identiphi.net.

PR contact: Chris Collier, 512-492-6220, Ext. 107 or ccollier@identiphi.net


'/>"/>
SOURCE IdentiPHI
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. Kinovate Life Sciences Launches Nittophase?High Performance Solid Support For Oligonucleatide Synthesis
2. UCLA launches $20 million stem cell institute to investigate HIV, cancer and neurological disorders
3. UNC launches study of liver injury caused by drugs
4. Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX
5. DOE JGI launches IMG public online microbial genome data clearinghouse
6. IMF Launches World’s First DNA Database for Myeloma Patients
7. Invitrogen Launches i-Path -- A Unique Systems Biology Platform at BIO 2005
8. NIEHS launches website with information for assessing environmental hazards from Hurricane Katrina
9. NIH launches comprehensive effort to explore cancer genomics
10. Virginia Bioinformatics Institutes launches microbial database
11. BioMed Central launches Biology Direct
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... long, spiky legs and their propensity for eating anything, ... nightmares. And now research from North Carolina State University ... homes across the eastern United States. , "The good ... any kind of threat to humans," says Dr. Mary ... lead author of a paper about the research. , ...
(Date:9/2/2014)... are done in by it. New research at Rockefeller ... stress gap in mice with very similar genetic backgrounds ... understand the development of psychiatric disorders such as anxiety ... experiences as it goes through its life. And we ... of genes, and as a result, affect an animal,s ...
(Date:9/1/2014)... diet showed some modest improvement in the last decade ... consumption of unhealthy trans fats, but the gap in ... poor. , , An unhealthy diet is closely linked ... healthy diet is an important part of the strategy ... diet quality is important because it can offer guidance ...
Breaking Biology News(10 mins):Researchers find Asian camel crickets now common in US homes 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3Quality of US diet improves, gap widens for quality between rich and poor 2Quality of US diet improves, gap widens for quality between rich and poor 3
... York, N.Y. (November 8, 2012) Autism Speaks, the world,s ... the release of biological and clinical data from 383 new ... to researchers. AGRE is a resource for scientists that is ... two or more children on the autism spectrum. These 383 ...
... least 126,000 sites across the U.S. have contaminated groundwater that ... considered "complex," meaning restoration is unlikely to be achieved in ... says a new report from the National Research Council. ... at these sites ranges from $110 billion to $127 billion, ...
... emerging field tissue regeneration, which harnesses the power and healing ... the world are turning their attention to. One of the ... State University, today announced the opening of SDSU,s new Integrated ... research in San Diego. Speaking at the Frontiers ...
Cached Biology News:Autism Speaks announces the release of new genetic data for researchers 2Report: Cleanup of some contaminated groundwater sites unlikely for decades 2Report: Cleanup of some contaminated groundwater sites unlikely for decades 3
(Date:9/2/2014)... MA (PRWEB) September 02, 2014 ... today the signage of a distribution agreement with ... is now distributing Myriant’s bio-succinic acid in the ... and Ireland, targeting customers in the industrial and ... distribution powerhouse, Azelis offers a far-reaching chemical portfolio ...
(Date:9/2/2014)... ROCKVILLE, Md. , Sept. 2, 2014 /PRNewswire/ ... of novel anti-infective biologic and drug candidates targeting ... announced today positive results from its final preclinical ... Drug Administration (FDA) guidance, this bridging study was ... product candidate designed to prevent the devastating effects ...
(Date:9/2/2014)... September 02, 2014 The inventors of ... for chronic tinnitus are seeking support for development costs ... Indiegogo platform ( http://igg.me/at/tinaway ), was launched on September ... therapeutic ‘mHealth’ app and is based on ten years ... team of biomedical and software engineers, Dr. Ian Dixon ...
(Date:8/31/2014)... 01, 2014 Available spectra is ... for research and cultivation of a wide range ... proprietary LEDs with proven patented and pending wide ... light uniformity in critical applications in contrast to ... , “Our customers have a large variety of ...
Breaking Biology Technology:Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5
... Pacira Pharmaceuticals, Inc., an,acute care specialty pharmaceutical company, today ... addition of a key senior,executive to the company,s management ... a seasoned biopharmaceutical executive with more than,30 years of ... Pacira as the founder and past Chairman and CEO ...
... WOODCLIFF LAKE, N.J., July 9 Par,Pharmaceutical Companies, Inc. ... shipment of 12.5mg and 25mg meclizine HCl tablets immediately. ... of the AB-rated,generic product., Par marketed meclizine prior ... in February 2008. Par has since qualified a new ...
... 9 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (TSX:,LOR, ... biopharmaceutical company,specializing in the research and development ... of cancer, today announced progress made in,the ... two,research studies on the Virulizin(R) mode of ...
Cached Biology Technology:Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management 2Par Pharmaceutical to Launch meclizine HCL Tablets 2Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 2Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 3Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 4Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 5Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 6